2 weeks ago

Natco Pharma Q1 profit slumps 57% on weak Lenalidomide sales

Natco Pharma Q1 profit slumps 57% on weak Lenalidomide sales
Natco Pharma Q1 net profit slumps 57% on weak Lenalidomide sales · thehansindia.com

Natco Pharma is a company in Mumbai, India, that makes medicines.

It makes many medicines, including a cancer-treating drug called lenalidomide.

The company shared its money results for the first three months ending June 2026.

Its profit fell by 57 percent compared with the same time last year.

This happened because sales of lenalidomide were much lower.

The company's total revenue also dropped sharply, mostly from medicines sold abroad.

However, some parts of the business grew, such as medicines sold inside India.

The company also spent less money, which helped a little.

Key facts

Company
Natco Pharma Ltd
Quarter
Q1 ended June 2026
Net Profit
Rs 206.5 crore (down 57% YoY)
Year-Ago Net Profit
Rs 480.3 crore
Revenue from Operations
Rs 735.2 crore (vs Rs 1,328.9 crore)
Total Expenses
Rs 608.8 crore (vs Rs 818.7 crore)
Domestic Formulations Revenue
Rs 136.4 crore (up from Rs 107 crore)
International Formulations Revenue
Rs 477.1 crore (down from Rs 1,120.9 crore)

Sources

Related news